List of Topics | GSOD 2027

01 Topics

Every session topic at GSOD 2027.

A complete, searchable index of session topics across 35 scientific sessions. Use this page to plan your attendance or to find the right call for your abstract submission.

01 Track

GLP-1 & Incretin Therapies

Semaglutide, tirzepatide and next-generation weight-loss medications.

Track details

SELECT, SURMOUNT-MMO and cardiovascular outcomes of GLP-1 RAs
Triple agonists: retatrutide GGG and survodutide phase 3 readouts
Oral incretins: orforglipron, OASIS oral semaglutide, danuglipron
CagriSema, mazdutide and amylin/glucagon co-agonism
SUMMIT HFpEF, FLOW kidney and ESSENCE MASH indication expansion
Weight regain on discontinuation and maintenance dosing strategies
Medicare coverage, compounded shortage exit and global access

02 Track

Bariatric Surgery

Sleeve gastrectomy, gastric bypass and metabolic surgery outcomes.

Track details

RYGB vs sleeve gastrectomy: 10-year SLEEVEPASS, SM-BOSS, STAMPEDE
Endoscopic sleeve gastroplasty (ESG): MERIT trial and durability
SADI-S and duodenal switch for super-obesity and diabetes
Post-sleeve GERD, Barrett surveillance and conversion to RYGB
Revisional surgery and pharmacotherapy for weight regain
Metabolic surgery in BMI 30–35 with type 2 diabetes
Lean mass and bone density preservation post-bariatric

03 Track

Childhood & Adolescent Obesity

Pediatric prevention, early intervention and family-based care.

Track details

AAP 2023 guideline: IHBLT, pharmacotherapy and surgery in youth
STEP TEENS and SURMOUNT adolescent GLP-1/GIP trial data
Teen-LABS: 10-year metabolic surgery outcomes in adolescents
Family-based behavioral therapy and parent-only models
Early-life origins: gestational diabetes, breastfeeding, ACEs
Screen time, sleep and adolescent eating behavior
School food policy and SNAP-Ed evidence

04 Track

Obesity Genetics & Epigenetics

Monogenic obesity, GWAS findings and precision weight medicine.

Track details

Setmelanotide in POMC, LEPR, PCSK1 and Bardet-Biedl syndrome
Monogenic obesity: when and how to genotype
Polygenic risk scores for early-onset and severe obesity
FTO, MC4R and leptin–melanocortin pathway biology
Epigenetic programming: DOHaD and transgenerational effects
Pharmacogenomics of GLP-1 RA response variability
Ancestry diversity in obesity GWAS and clinical translation

05 Track

Metabolic Syndrome

Insulin resistance, NAFLD and cardiometabolic risk.

Track details

AHA CKM syndrome staging and primary-care implementation
Resmetirom and the MASH pharmacotherapy pipeline
GLP-1 and GGG agonists in MASLD/MASH (ESSENCE, SYNERGY-NASH)
Sarcopenic obesity: lean-mass preservation during weight loss
SURMOUNT-OSA: tirzepatide for obstructive sleep apnea
Obesity-driven HFpEF and incretin-based therapy
Insulin resistance, ectopic fat and visceral adiposity imaging

06 Track

Behavioral & Lifestyle Interventions

Nutrition counseling, physical activity and CBT.

Track details

Mediterranean, VLCD and time-restricted eating: head-to-head data
Resistance training and protein targets for lean-mass preservation
CBT for binge eating disorder and emotional eating
AI-assisted dietary intake and continuous glucose monitoring
Look AHEAD long-term cardiovascular and weight outcomes
Behavioral therapy as adjunct to GLP-1 RA pharmacotherapy
Sleep, circadian rhythm and weight regulation

07 Track

Gut Microbiome & Metabolism

Bacterial diversity, bile acids and metabolic health.

Track details

Bile acid–FXR–FGF19 axis and obeticholic-class agents
Akkermansia muciniphila and next-generation probiotics
Microbiome shifts after RYGB and sleeve gastrectomy
Short-chain fatty acids, gut–brain axis and reward signaling
Microbiome predictors of GLP-1 RA response
Fecal microbiota transplantation in metabolic disease
Multi-omics and clinical trial standardization

08 Track

Health Equity in Obesity Care

Disparities, stigma and access to evidence-based care.

Track details

Weight stigma in clinical care and patient-first language
Race, ethnicity and rural disparities in GLP-1 prescribing
Medicare Part D, Treat and Reduce Obesity Act and policy reform
Social determinants and structural drivers of obesity
Culturally tailored lifestyle and behavioral interventions
Community-based participatory research and trust-building
Insurance prior authorization and step-therapy reform

09 Track

Policy, Environment & Prevention

Food environment, built environment and population-level policy.

Track details

Sugar-sweetened beverage taxes: Mexico, UK, Philadelphia outcomes
Ultra-processed foods, NOVA classification and NIH ward studies
Front-of-package warning labels and FDA Healthy claim
Restrictions on child-directed food marketing
Built environment: walkability, food access, transit
School food standards and USDA dietary guidelines
Obesity prevention in low- and middle-income countries

Have research aligned to one of these topics?

Submit your abstract by February 20, 2027. Oral and poster presentations are welcome across all nine tracks.

Submit Abstract